A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)
Phase 1
87
about 4.1 years
18+
34 sites in FL, GA, IN +8
About this study
Researchers are testing a treatment combination of elranatamab and iberdomide to see if it's safe and tolerable for people with relapsed or refractory multiple myeloma. The trial will also determine the correct dose of this combination for these patients.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Elranatamab
- 2.Take Iberdomide
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
elranatamab
Primary: Part 1: Number of participants with dose limiting toxicity (DLT), Part 2: Number of participants with Adverse Events (AE) by Seriousness and Relationship to Treatment
Secondary: Part 1 and Part 2: Duration of Response (DOR), Part 1 and Part 2: Number of Participants with Adverse Events (AE) characterized by type, frequency, severity, Part 1 and Part 2: Number of Participants with Clinically Significant Change from Baseline in Laboratory Abnormalities, Part 1 and Part 2: Percentage of Participants with Complete Response Rate (CRR), Part 1 and Part 2: Percentage of Participants with Objective Response Rate (ORR), Part 1 and Part 2: Time of Overall Survival (OS), Part 1 and Part 2: Time of Progression Free Survival (PFS), Part 1: Number of participants with Adverse Events (AE) by Seriousness and Relationship to Treatment
Oncology